TScan Therapeutics, Inc.
News
Insider Buying: TScan Therapeutics, Inc. (NASDAQ:TCRX) Director Acquires $28,450.00 in Stock
Ticker Report TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) Director Barbara Klencke purchased 5,000 shares of TScan Therapeutics stock in a transaction that occurred on Friday, August 23rd. The shares...\n more…
Barbara Klencke Buys 5,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock
Ticker Report TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) Director Barbara Klencke acquired 5,000 shares of the company's stock in a transaction on Monday, August 26th. The shares were bought at an...\n more…
TScan Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T...\n more…
TScan Therapeutics Director Acquires 18% More Stock
Simply Wall St Whilst it may not be a huge deal, we thought it was good to see that the TScan Therapeutics, Inc. ( NASDAQ:TCRX...\n more…
TScan Therapeutics, Inc. (NASDAQ:TCRX) Insider Sells $951,885.08 in Stock
Ticker Report TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) insider Zoran Zdraveski sold 164,686 shares of the business's stock in a transaction on Friday, August 23rd. The shares were sold at an...\n more…
Equities Analysts Set Expectations for TScan Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:TCRX)
Zolmax TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities research analysts at Wedbush dropped their FY2024 earnings per share estimates for TScan Therapeutics in a research report issued on...\n more…